BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Jump Financial LLC

Jump Financial LLC decreased its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRNFree Report) by 87.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,859 shares of the biotechnology company’s stock after selling 60,719 shares during the quarter. Jump Financial LLC’s holdings in BioMarin Pharmaceutical were worth $784,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. ICA Group Wealth Management LLC purchased a new stake in BioMarin Pharmaceutical in the 4th quarter valued at $31,000. MayTech Global Investments LLC acquired a new position in BioMarin Pharmaceutical in the 4th quarter valued at $36,000. Dark Forest Capital Management LP acquired a new position in BioMarin Pharmaceutical in the 1st quarter valued at $37,000. State of Wyoming acquired a new position in BioMarin Pharmaceutical in the 4th quarter valued at $41,000. Finally, Castleview Partners LLC acquired a new position in BioMarin Pharmaceutical in the 3rd quarter valued at $35,000. Hedge funds and other institutional investors own 92.78% of the company’s stock.

BioMarin Pharmaceutical Stock Down 0.2 %

Shares of NASDAQ:BMRN opened at $89.66 on Thursday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.65 and a current ratio of 2.54. The business’s 50 day simple moving average is $94.06 and its two-hundred day simple moving average is $89.90. BioMarin Pharmaceutical Inc. has a 52-week low of $76.02 and a 52-week high of $111.79. The firm has a market cap of $16.89 billion, a P/E ratio of 116.44, a PEG ratio of 0.99 and a beta of 0.31.

Insider Transactions at BioMarin Pharmaceutical

In related news, Director Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $98.19, for a total transaction of $981,900.00. Following the completion of the sale, the director now owns 425,162 shares of the company’s stock, valued at $41,746,656.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other BioMarin Pharmaceutical news, Director Jean Jacques Bienaime sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $98.19, for a total transaction of $981,900.00. Following the sale, the director now owns 425,162 shares in the company, valued at $41,746,656.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP George Eric Davis sold 13,764 shares of BioMarin Pharmaceutical stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $95.30, for a total value of $1,311,709.20. Following the completion of the transaction, the executive vice president now owns 55,710 shares in the company, valued at approximately $5,309,163. The disclosure for this sale can be found here. Insiders sold 33,764 shares of company stock valued at $3,233,509 over the last three months. Company insiders own 1.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Sanford C. Bernstein raised shares of BioMarin Pharmaceutical from an “underperform” rating to a “market perform” rating and set a $82.00 price objective on the stock in a research note on Monday, October 23rd. Piper Sandler dropped their price objective on shares of BioMarin Pharmaceutical from $125.00 to $115.00 and set an “overweight” rating on the stock in a research note on Thursday, November 2nd. Stifel Nicolaus reaffirmed a “buy” rating and set a $101.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, December 21st. BMO Capital Markets lowered their price target on shares of BioMarin Pharmaceutical from $102.00 to $100.00 and set an “outperform” rating on the stock in a research note on Friday, November 3rd. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $100.00 price target on shares of BioMarin Pharmaceutical in a research note on Tuesday, November 7th. Nine analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $110.16.

Get Our Latest Report on BioMarin Pharmaceutical

BioMarin Pharmaceutical Profile

(Free Report)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Read More

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.